Grubstein A, et al. - Researchers compared background parenchymal enhancement and amount of fibroglandular tissue on breast magnetic resonance imaging between BRCA mutation carriers and non-carriers, to ultimately assess the potential implications of the findings for short-term follow-up. Relative to age-matched non-carriers, lower levels of breast parenchymal enhancement and amount of fibroglandular tissue were detected in BRCA mutation carriers. A possible influence of hormonal status on these differences was suggested. Moreover, in distinctive subgroups of breast cancer (hormone-enriched, mutation-associated defective DNA damage repair), different risks were suggested by these differences. The rate of Breast Imaging Reporting and Data System (BI-RADS) 3 in the control group was higher and probably attributed to the differences in the indications for imaging between the carrier and non-carrier groups (screening for mutations and breast cancer evaluation, respectively).